|
YOD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.36800000216653E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.03729999992808E-07 |
| Normal-vs-Stage2 |
7.59810000000583E-05 |
| Normal-vs-Stage3 |
8.05430000472285E-09 |
| Normal-vs-Stage4 |
3.386400E-04 |
| Stage1-vs-Stage2 |
6.453200E-01 |
| Stage1-vs-Stage3 |
7.417500E-02 |
| Stage1-vs-Stage4 |
9.121400E-01 |
| Stage2-vs-Stage3 |
4.030800E-01 |
| Stage2-vs-Stage4 |
7.825000E-01 |
| Stage3-vs-Stage4 |
2.513000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.95770002828522E-09 |
| Normal-vs-AfricanAmerican |
2.252800E-01 |
| Normal-vs-Asian |
1.74490000004468E-06 |
| Caucasian-vs-AfricanAmerican |
1.084310E-02 |
| Caucasian-vs-Asian |
6.964800E-01 |
| AfricanAmerican-vs-Asian |
3.294100E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.08429999995985E-07 |
| Normal-vs-Female |
4.06729999680167E-08 |
| Male-vs-Female |
8.311000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.18200000001723E-06 |
| Normal-vs-Age(41-60Yrs) |
6.41480000229677E-08 |
| Normal-vs-Age(61-80Yrs) |
3.91590000000663E-05 |
| Normal-vs-Age(81-100Yrs) |
5.763900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.473800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.629400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.586400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.969000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.374200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.580800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.398110E-04 |
| Classical-VS-Follicular |
4.271400E-01 |
| Classical-VS-Other |
8.294200E-01 |
| Classical-VS-Normal |
1.8696000003704E-07 |
| Tall-VS-Follicular |
2.607500E-04 |
| Tall-VS-Other |
9.337800E-02 |
| Tall-VS-Normal |
1.15900000707825E-09 |
| Follicular-VS-Other |
6.755400E-01 |
| Follicular-VS-Normal |
7.594600E-04 |
| Other-VS-Normal |
4.736500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.25280000396711E-08 |
| Normal-vs-N1 |
1.31309999995555E-06 |
| N0-vs-N1 |
3.436000E-01 |
|
|
